Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arena Pharmaceuticals
Biotech
Connect uncouples from Pfizer by scrapping eczema pact
Connect licensed the oral, peripherally acting H3R antagonist in 2012 from Arena, a company that Pfizer bought for $6.7 billion a decade later.
Nick Paul Taylor
Apr 17, 2024 6:38am
Former Arena CEO takes over new RNA biotech—Chutes & Ladders
May 26, 2023 9:30am
New RNA biotech raises $300M in largest private round of 2023
May 23, 2023 6:30am
Pfizer tosses newly acquired meds out of the Arena
May 2, 2023 1:40pm
Pfizer's Arena goal? Get out of the way
May 24, 2022 6:45am
Aquestive CEO departs with seizure med in limbo—Chutes & Ladders
May 20, 2022 9:30am
